Home Compare BIM.PA
Peer Analysis

bioMérieux S.A. — Peer Companies & Stock Comparisons

bioMérieux S.A.'s functional peer companies ranked by peer score — growth, valuation, profitability and stability compared.

Compare BIM.PA with peers
Comparison BIM.PA peer score
bioMérieux S.A. vs Eurofins Scientific SE
41 Compare →
bioMérieux S.A. vs Straumann Holding AG
39 Compare →
bioMérieux S.A. vs HCA Healthcare, Inc.
70 Compare →
bioMérieux S.A. vs Compagnie Générale des Établissements Michelin Société en commandite par actions
60 Compare →
bioMérieux S.A. vs Hikma Pharmaceuticals PLC
53 Compare →
bioMérieux S.A. vs West Pharmaceutical Services, Inc.
67 Compare →
bioMérieux S.A. vs Siegfried Holding AG
44 Compare →
bioMérieux S.A. vs Convatec Group PLC
38 Compare →
bioMérieux S.A. vs Viscofan, S.A.
55 Compare →
bioMérieux S.A. vs Clean Harbors, Inc.
34 Compare →
bioMérieux S.A. vs PepsiCo, Inc.
70 Compare →

Full BIM.PA analysis in AssetNext

View the complete bioMérieux S.A. report including all peer dimensions.

Open in AssetNext →

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.